Every material Form 8-K Liminatus Pharma, Inc. has filed with the SEC since August 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Liminatus Pharma agreed on November 2, 2026 to sell 260,001 common shares at $2.50 each in a private placement to a non-U.S. investor, raising gross proceeds of $650,002.50. The company plans to use the proceeds for working capital and general corporate purposes, with closing expected on or about November 20, 2026. The company also agreed to file a resale registration statement within 60 days of closing, which could add shares that may be sold into the market later.
Shares: 260,001 common shares at $2.50 per share
Gross proceeds: $650,002.50, for working capital and general corporate purposes
Expected closing: on or about November 20, 2026
Company must file a resale registration statement with the SEC within 60 days of closing
Nasdaq has determined that Liminatus Pharma regained compliance with its minimum bid price rule and closed the matter, according to an 8-K filed September 29, 2026. The company had transferred to The Nasdaq Capital Market effective August 4, 2026, after a hearing before the Nasdaq Hearings Panel, and completed a 1-for-50 reverse stock split on August 20, 2026. Its closing bid price was above $1.00 for 13 consecutive trading days, from August 21 to September 9, 2026.
Nasdaq notice dated September 24, 2026 said the company regained compliance with the Bid Price Rule and the matter is closed.
Closing bid price was above $1.00 for 13 consecutive trading days, August 21 to September 9, 2026.
The company effected a 1-for-50 reverse stock split at the close of trading on August 20, 2026.
Company issued a press release on September 29, 2026 (Exhibit 99.1) announcing the regained compliance.
Liminatus Pharma said it will carry out a 1-for-50 reverse stock split of its common stock, effective August 20, 2026, so its shares can meet Nasdaq's $1.00 minimum bid price. The company remains listed under a Nasdaq Panel exception, but it must show a $1.00 closing bid for at least ten consecutive trading days by September 3, 2026, and the company says it cannot assure it will do so.
Reverse split ratio of 1-for-50, with split-adjusted trading under LIMN on The Nasdaq Capital Market expected at the market open on August 21, 2026
New CUSIP number 53271X 207; fractional shares will be rounded up to the nearest whole share, with no cash paid for fractions
Based on July 2, 2026 figures, outstanding shares would fall from 67,160,362 to approximately 1,343,208
Nasdaq Panel extended the deadline to demonstrate compliance with Listing Rule 5550(a)(2) to September 3, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Liminatus Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →